How much can tirzepatide lower A1c in type 2 diabetes?

In SURPASS-2, mean HbA1c fell by 2.01, 2.24 and 2.30 percentage points across the 5, 10 and 15 mg tirzepatide groups at 40 weeks, from a mean baseline of 8.28%. Other SURPASS trials reported reductions in a similar broad range, but the starting HbA1c, background medication, dose reached and individual response all affect the result.

Is tirzepatide the same as insulin?

No. Tirzepatide activates the GIP and GLP-1 receptors and supports glucose-dependent insulin release, while injected insulin directly supplies insulin. SURPASS-3 compared tirzepatide with insulin degludec, and SURPASS-5 studied tirzepatide added to insulin glargine. Those are different treatment roles, and a prescriber decides how they fit into an individual plan.

Can tirzepatide cause low blood sugar?

Yes, although the risk is generally lower when tirzepatide is used without insulin or a sulfonylurea. The risk rises when it is combined with either because those treatments can lower glucose independently. A prescriber reviews the full medication list, glucose patterns and hypoglycemia history before deciding whether another diabetes medication needs adjustment.

Can tirzepatide be used with basal insulin?

Yes, in some treatment plans. SURPASS-5 studied tirzepatide added to titrated insulin glargine in adults whose type 2 diabetes remained inadequately controlled. That does not provide a self-directed protocol. Combining the two changes hypoglycemia considerations, so the reviewing clinician determines the insulin plan and the actual tirzepatide dose.

What does a prescriber check before considering tirzepatide?

The review typically includes HbA1c and glucose patterns, kidney function, current diabetes medication, prior hypoglycemia, digestive and pancreatic history, diabetic retinopathy, pregnancy status, and personal or family history of medullary thyroid carcinoma or MEN 2. These factors help determine whether tirzepatide fits and whether other medication may need adjustment.

Is compounded tirzepatide the same as Mounjaro?

No. Mounjaro is a branded product made under an approved drug application. Compounded tirzepatide is prepared by a licensed compounding pharmacy for an individual prescription and is not a generic copy of Mounjaro. The products follow different manufacturing and regulatory pathways even though tirzepatide is the named active ingredient.

Tirzepatide for Type 2 Diabetes: Trial Results

Tirzepatide for type 2 diabetes has been associated with substantial reductions in HbA1c in randomized trials, including when compared with semaglutide 1 mg or basal insulin. In SURPASS-2, the mean reduction was 2.01–2.30 percentage points at 40 weeks across three tirzepatide groups, versus 1.86 points with semaglutide. Those are group averages, not a promise for one person. Tirzepatide does not erase the diagnosis, and treatment still sits inside a broader diabetes plan that may include nutrition, movement, glucose monitoring and other medication.

Tirzepatide for type 2 diabetes: what it targets

HbA1c estimates average blood glucose over roughly three months. Tirzepatide activates receptors for two incretin hormones, GIP and GLP-1. When glucose is elevated, those signals support insulin release and reduce glucagon; GLP-1 signaling also slows gastric emptying and affects appetite. The combined effect can change both fasting and after-meal glucose. The receptor biology is covered in detail in how tirzepatide works.

Because the insulin response is glucose-dependent, tirzepatide used without insulin or a sulfonylurea generally has a lower hypoglycemia risk than insulin therapy. That risk changes when treatments are combined. The HbA1c response also depends on starting HbA1c, dose reached, adherence, illness and other medication. Trial averages establish a useful range, not an individual forecast. Two people who begin with different glucose patterns and treatment histories may not have the same response at the same dose.

SURPASS-2: tirzepatide versus semaglutide

SURPASS-2 enrolled 1,879 adults whose type 2 diabetes was not adequately controlled with metformin. Their mean starting HbA1c was 8.28%. Participants were assigned to tirzepatide 5, 10 or 15 mg, or semaglutide 1 mg, for 40 weeks. The trial used gradual escalation to reach the assigned tirzepatide dose; it was not a schedule for self-directed dosing.

Trial group	Mean HbA1c change	Weight difference vs semaglutide
Tirzepatide 5 mg	−2.01 percentage points	−1.9 kg
Tirzepatide 10 mg	−2.24 percentage points	−3.6 kg
Tirzepatide 15 mg	−2.30 percentage points	−5.5 kg
Semaglutide 1 mg	−1.86 percentage points	Reference

All three tirzepatide groups met the trial's statistical criteria for superiority on HbA1c versus semaglutide 1 mg. Gastrointestinal events were the most common adverse effects in both groups. The comparison is specific to semaglutide 1 mg, not every semaglutide dose or formulation (Frías et al., New England Journal of Medicine, 2021). The sibling guide to semaglutide for type 2 diabetes covers that medication on its own terms.

What SURPASS-1, SURPASS-3 and SURPASS-5 add

The rest of the program tested tirzepatide at different points in diabetes care:

SURPASS-1 studied 478 adults using diet and exercise without diabetes medication. At 40 weeks, mean HbA1c changed by −1.87 to −2.07 percentage points across tirzepatide groups versus +0.04 with placebo (Rosenstock et al., The Lancet, 2021).
SURPASS-3 enrolled adults taking metformin, with or without an SGLT2 inhibitor. At 52 weeks, HbA1c fell by 1.93 to 2.37 points with tirzepatide and 1.34 points with titrated insulin degludec (Ludvik et al., The Lancet, 2021).
SURPASS-5 added tirzepatide or placebo to insulin glargine, with or without metformin. At 40 weeks, HbA1c fell by 2.11 to 2.40 points across tirzepatide groups versus 0.86 points with placebo (Dahl et al., JAMA, 2022).

These studies do not show that one result transfers unchanged to every treatment plan. They show effects across monotherapy, oral-drug and basal-insulin settings. The tirzepatide clinical trials overview places the wider program in context.

What SURPASS-CVOT established about cardiovascular safety

SURPASS-CVOT addressed a different question: whether cardiovascular outcomes with tirzepatide were no worse than those with dulaglutide in people who already had type 2 diabetes and atherosclerotic cardiovascular disease. In the modified analysis of 13,165 participants, cardiovascular death, heart attack or stroke occurred in 12.2% assigned to tirzepatide and 13.1% assigned to dulaglutide.

The hazard ratio was 0.92, with a 95.3% confidence interval of 0.83 to 1.01. Tirzepatide met the prespecified test for noninferiority but not the test for superiority. That is evidence of cardiovascular safety relative to an active comparator with established benefit; it is not proof that tirzepatide prevents an event for a particular person (Nicholls et al., New England Journal of Medicine, 2025).

What a prescriber reviews before treatment

Tirzepatide may enter the discussion when HbA1c remains above an individualized goal, especially when weight and glucose management both matter. A prescriber looks beyond one lab value. The review includes recent HbA1c and glucose patterns, kidney function, hydration risk, digestive history, diabetic retinopathy history, pregnancy status and any personal or family history of medullary thyroid carcinoma or MEN 2.

The medication list matters just as much. Insulin and sulfonylureas can increase hypoglycemia risk when used with tirzepatide, so the clinician decides whether another treatment needs adjustment and sets the actual tirzepatide dose. Kidney impairment does not automatically exclude tirzepatide, but kidney function affects the broader diabetes plan and becomes especially relevant if nausea, vomiting or diarrhea leads to dehydration.

A licensed provider reviews every request, and not everyone qualifies. The decision depends on the whole clinical picture rather than a single HbA1c threshold.

Brand and compounded tirzepatide are different products

Through Promise, tirzepatide is dispensed as a compounded medication, which is different from an FDA-approved product: the formulation offered here is not FDA-approved. The compounded preparation is not Mounjaro, the brand that received FDA approval in May 2022 as an adjunct to diet and exercise for improving glycemic control in adults with type 2 diabetes.

Compounding and brand manufacturing follow different regulatory pathways. A compounded preparation is made by a licensed U.S. compounding pharmacy for an individual prescription; it is not a generic Mounjaro product and has not gone through the brand's FDA review. That regulatory distinction does not decide the clinical question by itself. A licensed provider may still prescribe a compounded formulation where they judge it appropriate; that decision is between the patient and the doctor.

The practical standard is therefore more than a low A1c number. It is a measured response, tolerable adverse effects and a treatment plan that remains appropriate as other medications and health conditions change.